{"schema_version":"1.0","type":"article","title":"GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall","url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.md","lang":"en","date":"2026-08-15","publish_at":"2026-08-15T09:30:00+08:00","updated_at":"2026-08-15","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","GSK","camlipixant","P2X3","refractory chronic cough","CALM-1","CALM-2","Phase 3","drug development","biopharma M&A"],"summary":"After GSK's roughly US$2 billion acquisition of BELLUS Health, CALM-1 met its endpoint but CALM-2 did not reproduce the result. The divergence shows why Phase 2 promise, patient experience and reproducibility must move together.","key_points":[],"facts":[],"sections":[],"references":[{"title":"[GSK, CALM-1 and CALM-2 Phase 3 update, 17 July 2026]","source":"","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials/"},{"title":"[GSK, agreement to acquire BELLUS Health, 18 April 2023]","source":"","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-bellus-health/"},{"title":"[GSK, completion of the BELLUS Health acquisition, 28 June 2023]","source":"","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-bellus-health/"},{"title":"[SOOTHE original peer-reviewed Phase 2b paper, NCT04678206]","source":"","date":"","url":"https://academic.oup.com/ajrccm/article/211/6/1038/8513749"},{"title":"[ClinicalTrials.gov: SOOTHE, NCT04678206]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT04678206"},{"title":"[GSK, J.P. Morgan Healthcare Conference transcript]","source":"","date":"","url":"https://www.gsk.com/media/tsvlrat3/jp-morgan-healthcare-conference-transcript.pdf"},{"title":"[ClinicalTrials.gov: CALM-1, NCT05599191]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05599191"},{"title":"[ClinicalTrials.gov: CALM-2, NCT05600777]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05600777"},{"title":"[ClinicalTrials.gov: BALANCE, NCT07519395]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07519395"}],"images":[{"alt":"Figure 1 | The same drug and dose produced different pivotal outcomes in CALM-1 and CALM-2.","url":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/figure-01.svg"},{"alt":"Figure 2 | SOOTHE created a strong Phase 2 signal; the US$2 billion acquisition purchased a late-stage hypothesis, not a guaranteed approval.","url":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/figure-02.svg"},{"alt":"Figure 3 | Phase 3 retests an early signal across a larger, more heterogeneous population, longer follow-up and reproducibility requirements.","url":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/figure-03.svg"},{"alt":"Figure 4 | GSK stopped refractory chronic cough development, while the Phase 2b BALANCE study in IBS continues.","url":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/figure-04.svg"}],"cover_image":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/cover-v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-15）。GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall。https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}